PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,369 cases. Vaccination status has also been added, as this data is especially important at the current time, given the emergence of novel variants of concern such as Omicron. Below is a summary of the data collected or
view the full report on the PsoProtect website.
Average age: 49 years
Phenotype of psoriasis: 1,335 plaque psoriasis, 34 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 10 days
Cases reported by country of assessment (≥20 cases):
Severity of psoriasis at time of onset of COVID-19 (PGA):
Hospitalization required due to COVID-19:
In addition to demographics, PsoProtect collects the following types of de-identified data:
- Psoriasis disease characteristics, comorbidities and systemic treatment for psoriasis at onset of COVID-19
- COVID-19 characteristics and disease course
- COVID-19 outcome
We encourage clinicians to continue reporting cases of COVID-19 (suspected or confirmed) in psoriasis via the simple online PsoProtect case report form.
*Data are preliminary and include a limited number of cases and should not be used to inform clinical decision making.
Tags: psoprotect, covid-19, psoriasis